Severe exfoliative dermatitis induced by apalutamide in a mHSPC patient: A case report - PubMed
7 days ago
- #prostate cancer
- #exfoliative dermatitis
- #apalutamide
- Apalutamide is used to treat metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer.
- Severe exfoliative dermatitis, a rare but serious skin adverse reaction, was reported in a patient taking apalutamide.
- Treatment included gamma globulin, antibiotics, antihistamines, and topical hydrocortisone cream.
- The patient's condition improved with red skin and minimal desquamation remaining.
- Apalutamide should be discontinued immediately if severe skin reactions are suspected.